EADV 2025｜聚焦儿童特应性皮炎

在今年的EADV大会上，Carsten Flohr教授分享了儿童特应性皮炎领域的最新突破。Carsten Flohr教授强调，特应性皮炎在症状出现之前就已存在——最早在婴儿两周大时就可检测到天然保湿因子、皮肤脂质和微生物组的异常。这种“冰山”现象为早期干预带来了可能。

一项前景广阔的预防策略是在婴儿中广泛使用润肤剂。美国一项针对1200名儿童的随机试验表明，规律使用润肤剂可显著降低特应性皮炎的发病率。

在治疗方面，Carsten Flohr教授探讨了新型系统性药物，如OX40配体拮抗剂（预计未来几年可应用的注射剂），以及一种新的外用乳膏——Tapinarof（一种AHR拮抗剂），该药物在低至两岁的儿童中显示出约40%的改善。

他还介绍了由他领导、在国际皮肤科学会联盟支持下的“全球特应性皮炎图谱”（GADA）国际项目。GADA旨在通过持续的证据整合和研究方法共识，绘制全球特应性皮炎疾病负担，尤其是在研究不足的地区。此外，紫外线暴露（可能具有保护作用）和空气污染（风险因素）等环境因素也被指出是特应性皮炎发病的重要影响因素。

At this year's EADV session, Prof. Carsten Flohr, Chair of Dermatology at King's College London and a leading pediatric dermatologist, shared the latest breakthroughs in atopic dermatitis (AD), especially in children.

He highlighted that AD may begin long before visible symptoms appear — as early as two weeks of age — with detectable changes in natural moisturizing factor, skin lipids, and microbiome. This ""iceberg"" phenomenon opens doors for early intervention.

One promising prevention strategy is the broad use of emollients in infants. A U.S. randomized trial with 1,200 children showed significantly reduced AD incidence with regular emollient application.

On the treatment front, Prof. Flohr discussed novel systemic therapies like OX40 ligand antagonists (injectables expected in coming years) and a new topical cream — tapinarof, an AHR antagonist — which has shown ~40% improvement in children as young as two.

He also introduced the Global Atopic Dermatitis Atlas (GADA), an international initiative he leads under the International League of Dermatological Societies. GADA aims to map AD burden globally, especially in understudied regions, through ongoing evidence synthesis and consensus on research methods.

Environmental factors like UV exposure (potentially protective) and air pollution (a risk factor) were also noted as key influencers in AD development.

To learn more, visit: www.atopicdermatitisatlas.org